Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 4, 1996, Pages 366-372

  Ikeda, T ^a   Sato, C ^a   Noguchi, O ^a   Kobayashi, F ^a   Tozuka, S ^a   Sakamoto, S ^a   Marumo, F ^a  

^a YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

peripheral blood lymphocyte subsets; primary biliary cirrhosis; ursodeoxycholic acid therapy

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0029985965     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01385.x     Document Type: Article

References (35)

1. 1 Klatskin G., Kantor FS. Mitochondrial antibody in primary biliary cirrhosis and other diseases. Ann. Intern. Med. 1972 ; 77: 533–41.
2. 2 Sherlock S. Primary biliary cirrhosis. Prog. Liver Dis. 1976 ; 5: 559–74.
3. 3 Nouri‐Aria KT, Hegarty JE, Neuberger J., Eddleston ALWF, Williams R. In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. Clin. Exp. Immunol. 1985 ; 61: 297–304.
4. 4 James SP, Jones EA, Hoofnagle JH, Strober W. Circulating activated B‐cells in primary biliary cirrhosis. J. Clin. Immunol. 1985 ; 5: 524–60.
5. 5 Bhan A., Dienstag J., Schlossman SF, Reinherz E. Alteration of T‐cell subsets in primary biliary cirrhosis. Clin. Exp. Immunol. 1982 ; 47: 351–8.
6. 6 Björkland A., Festin R., Mendel‐Hartvig I., Nyberg A., Lööf L., Tötterman T. Blood and liver‐infiltrating lymphocytes in primary biliary cirrhosis: Increase in activated T and natural killer cells and recruitment of primed memory T cells. Hepatology 1991 ; 13: 1106–11.
7. 7 Heathcote J., Ross A., Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976 ; 70: 656–60.
8. 8 Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OFW. A pilot, double‐blind, controlled 1 year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss. Hepatology 1989 ; 10: 420–9.
9. 9 Wiesner RH, Ludwig J., Lindor KD et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1990 ; 322: 1419–24.
10. 10 Poupon R., Chrètien Y., Poupon RE, Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis ? Lancet 1987 ; i: 834–6.
11. 11 Poupon RE, Eschwege E., Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: Interim analysis of a double‐blind multicentre randomized trial. J. Hepatol. 1990 ; 11: 16–21.
12. 12 Poupon RE, Balkau B., Eschwege E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1991 ; 324: 1548–54.
13. 13 Battezzati PM, Podda M., Bianchi FB et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: Preliminary analysis of a double‐blind multicenter trial. J. Hepatol. 1993 ; 17: 332–8.
14. 14 Yoshikawa M., Tsujii T., Matsumura K. et al. Immunomo‐dulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992 ; 16: 358–64.
15. 15 Scheuer PJ. Primary biliary cirrhosis. Proc. R. Soc. Med. 1967 ; 60: 1257–60.
16. 16 Böyum A. Isolation of mononuclear cells and granulocytes from blood. Scand. J. Clin. Lab. Invest. 1968 ; 21: 77–89.
17. 17 Wiesner RH, Grambsch PM, Lindor KD, Ludwig J., Dickson ER. Clinical and statistical analysis of new and evolving therapies for primary biliary cirrhosis. Hepatology 1988 ; 8: 668–76.
18. 18 Miller KB, Elta G., Rudder R., Kaplan M. Lymphocyte subsets in primary biliary cirrhosis. Ann. Int. Med. 1984 ; 100: 385–7.
19. 19 Zetterman RK, Woltjen JA. Suppressor cell activity in primary biliary cirrhosis. Dig. Dis. Sci. 1980 ; 5: 104–7.
20. 20 Miller KB, Sepersky RA, Brown KM, Goldberg MJ, Kaplan MM. Genetic abnormalities of immunoregulation in primary biliary cirrhosis. Am. J. Med. 1983 ; 75: 75–80.
21. 21 Ikeda T., Uchihara M., Daiguji Y., Hasumura Y., Takeuchi J. In vitro effect of corticosteroid on immunoregulatory functions in primary biliary cirrhosis. Clin. Immunol. Immunopathol. 1989 ; 53: 192–201.
22. 22 Morimoto C., Letvin NL, Distaso JA, Aldrich WR, Schlossman SF. The isolation and characterization of the human suppressor inducer T cell subset. J. Immunol. 1985 ; 134: 1508–15.
23. 23 Hoffman AF. Bile acid hepatotoxicity and rationale of UDCA therapy in chronic cholestatic liver disease: Some hypotheses. In: Paumgartner G., Stiehl A., Barbara L., Roda E., eds. Strategies for the Treatment of Hepatobiliary Diseases. Dordrecht: Kluwer Academic, 1990 ; 13–33.
24. 24 Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In: Paumgartner G., Stiehl A., Barbara L., Roda E., eds. Strategies for the Treatment of Hepatobiliary Diseases. Dordrecht: Kluwer Academic, 1990 ; 43–56.
25. 25 Leuschner U., Fischer H., Kurtz W. et al. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double‐blind trial. Gastroenterology 1989 ; 97: 1268–74.
26. 26 Crosignani A., Podda M., Battezzati PM et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991 ; 14: 1000–7.
27. 27 Ballardini G., Bianchi FB, Mirakian R., Fallani M., Pisi E., Bottazzo GF. HLA‐A, B, C, HLA‐D/DR and HLA‐D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin. Exp. Immunol. 1987 ; 70: 35–46.
28. 28 Ballardini G., Mirakian R., Bianchi FB, Pisi E., Doniach D., Bottazzo GF. Aberrant expression of HLA‐DR antigens on bile duct epithelium in primary biliary cirrhosis: Relevance to pathogenesis. Lancet 1984 ; ii: 1009–13.
29. 29 Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990 ; 11: 12–15.
30. 30 Leuschner U., Dienes HP, Guldutuna S., Birfkenfeld G., Leuschner M. Ursodeoxycholic acid (UDCA) influences immune parameters in patients with primary biliary cirrhosis (PBC). Hepatology 1990 ; 12: 957 (Abstract).
31. 31 Clement LT, Dagg MK, Landly A. Characterization of human lymphocyte subpopulations: Alloreactive cytotoxic precursor and effector cells are phenotypically distinct from Leu2 + T‐lymphocyte suppressor cells. J. Clin. Immunol. 1984 ; 4: 395–402.
32. 32 Meuer SC, Moebius U., Manns M. et al. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur. J. Immunol. 1988 ; 18: 1447–52.
33. 33 Spits H., Borst J., Tax W., Capel PJA, Terhorst C., DeVries JE. Characteristics of a monoclonal antibody (WT31) that recognizes a common epitope on the human T cell receptor for antigen. J. Immunol. 1985 ; 135: 1922–8.
34. 34 Borst J., Van Dongen JJM, Bolhuis RLH et al. Distinct molecular forms of human T cell receptor γ/δ detected on viable T cells by a monoclonal antibody. J. Exp. Med. 1988 ; 167: 1625–44.
35. 35 Hashimoto Y., Maxam AM, Greene MI. T‐cell antigen‐receptor genes in autoimmune mice. Proc. Natl Acad. Sci. USA 1986 ; 83: 7865–9.